MDxHealth SA (MDXH)
$2.8
+0.10 (+3.70%)
Rating:
Recommendation:
-
| Symbol | MDXH |
|---|---|
| Price | $2.8 |
| Beta | 0.871 |
| Volume Avg. | 0.08M |
| Market Cap | 80.597M |
| Shares () | - |
| 52 Week Range | 2.47-8.51 |
| 1y Target Est | - |
| DCF Unlevered | MDXH DCF -> | |
|---|---|---|
| DCF Levered | MDXH LDCF -> | |
| ROE | -215.63% | Strong Sell |
| ROA | -35.97% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 152.26% | Buy |
| P/E | -1.18 | Sell |
| P/B | 2.46 | Strong Buy |
Latest MDXH news
About
Download (Excel)Mr. Michael K. McGarrity
Healthcare
Diagnostics & Research
NASDAQ Capital Market
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.